Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients.
Investigation of the effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood concentrations in stable transplant patients found that CYP 3A5*1/*3 polymorphism explained up to 45% of the variability in dose requirement in relation to tacolimus use.
Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus Conference
The importance of obtaining multicenter prospective trials to assess the efficacy of alternative strategies to TAC trough concentrations is emphasized, and single time points, limited sampling strategies, and area under concentration-time curve have all been considered to determine the most appropriate sampling procedure that correlates with efficacy.
CYP3A5 and ABCB1 Polymorphisms and Tacrolimus Pharmacokinetics in Renal Transplant Candidates: Guidelines from an Experimental Study
- V. Haufroid, P. Wallemacq, +6 authors M. Mourad
- MedicineAmerican journal of transplantation : official…
- 1 November 2006
This study confirms the very significant effect of CYP3A5 polymorphism early after the first administration of tacrolimus (Tac) and provides a strong argument for a doubling of the loading dose in patients early identified a priori on the transplantation list as possessing at least one CYP 3A5*1 allele.
Comparative Clinical Pharmacokinetics of Tacrolimus in Paediatric and Adult Patients
The rate and extent of tacrolimus absorption after oral administration do not seem to be altered in paediatric patients, but oral doses need to be generally 2-fold higher than corresponding adult doses to reach similar tacolimus blood concentrations.
Azithromycin reduces exaggerated cytokine production by M1 alveolar macrophages in cystic fibrosis.
- Magali Meyer, F. Huaux, +7 authors T. Leal
- Biology, MedicineAmerican journal of respiratory cell and…
- 26 November 2009
It is shown that CF macrophages are ubiquitously accumulated, and that these cells are polarized toward classical and alternative activation status, and the effect of azithromycin down-regulates inflammatory cytokine production by M1-polarized CF alveolarmacrophages.
Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil.
A pharmacokinetic/pharmacodynamic relationship between MPA and clinical events is demonstrated and it is suggested that dividing the MMF daily oral dose into more than two divided doses might prevent early MPA toxicity.
Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock
As patients with severe sepsis and septic shock have an increased Vd, a first dose of ≥ 25 mg/kg (total body weight) of amikacin is required to reach therapeutic peak concentrations, however, even with this higher amkacin dose, the peak concentration remained below therapeutic target levels in about one third of these patients.
CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation.
The ABCB1 1199G>A, 3435C>T and 2677G>T/A SNPs, appeared to reduce the activity of P-glycoprotein towards Tac, increasing Tac PBMC concentrations, which might enhance immunosuppressive status and prevention or rejection.
Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock
Standard dosage regimens for piperacillin-tazobactam, ceftazidime and cefepime may be insufficient to empirically cover less susceptible pathogens in the early phase of severe sepsis and septic shock.
Azithromycin reduces spontaneous and induced inflammation in ΔF508 cystic fibrosis mice
These findings further support the concept that inflammatory responses are upregulated in cystic fibrosis, and postulate that some of the benefits of azithromycin treatment in cysts fibrosis patients are due to modulation of lung inflammation.